Venetoclax was granted Breakthrough Therapy Designation by the FDA 6th june 2015. for the treatment of chronic lymphocytic leukemia in previously treated patients with the 17p deletion genetic mutation.
Venetoclax is sponsored by AbbVie, and is being developed in partnership with Genentech and Roche.
Venetoclax is an investigational oral B-cell lymphoma-2 inhibitor being evaluated for the treatment of patients with various cancer types. The BCL-2 protein prevents apoptosis of some cells, including lymphocytes, and can be expressed in some cancer types. Venetoclax is currently being evaluated in phase II and phase III clinical trials for the treatment of CLL, along with studies in several other cancers.